Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pavel Mozgunov

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Statistics in Medicine|December 21, 2019
Improving safety of the continual reassessment method via a modified allocation rulePavel Mozgunov, Thomas Jaki
Statistics in Medicine|May 27, 2026
Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical TrialsWeishi Chen, Pavel Mozgunov
Journal of the Royal Statistical Society. Series C, Applied Statistics|April 23, 2019
An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicityPavel Mozgunov, Thomas Jaki
Biometrical Journal. Biometrische Zeitschrift|July 13, 2019
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpointsPavel Mozgunov, Thomas Jaki
Statistics in Medicine|January 24, 2025
On Inclusion of Covariates in Model Based Dose Finding Clinical Trial DesignsAdrien Ollier, Pavel Mozgunov
Statistical Methods in Medical Research|April 28, 2020
A surface-free design for phase I dual-agent combination trialsPavel Mozgunov, Mauro Gasparini, Thomas Jaki
Computational Statistics & Data Analysis|June 4, 2021
Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measuresKsenia Kasianova, Mark Kelbert, Pavel Mozgunov
Biostatistics (Oxford, England)|August 31, 2018
A benchmark for dose finding studies with continuous outcomesPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Statistics in Medicine|May 9, 2023
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment orderingAlessandra Serra, Pavel Mozgunov, Thomas Jaki
Biometrical Journal. Biometrische Zeitschrift|June 13, 2020
Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studiesPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Statistics in Medicine|December 21, 2019
Improving safety of the continual reassessment method via a modified allocation rulePavel Mozgunov, Thomas Jaki
Statistics in Medicine|May 27, 2026
Computationally Efficient Approach to Operational Prior Specification in Phase I Clinical TrialsWeishi Chen, Pavel Mozgunov
Journal of the Royal Statistical Society. Series C, Applied Statistics|April 23, 2019
An information theoretic phase I-II design for molecularly targeted agents that does not require an assumption of monotonicityPavel Mozgunov, Thomas Jaki
Biometrical Journal. Biometrische Zeitschrift|July 13, 2019
A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpointsPavel Mozgunov, Thomas Jaki
Statistics in Medicine|January 24, 2025
On Inclusion of Covariates in Model Based Dose Finding Clinical Trial DesignsAdrien Ollier, Pavel Mozgunov
Statistical Methods in Medical Research|April 28, 2020
A surface-free design for phase I dual-agent combination trialsPavel Mozgunov, Mauro Gasparini, Thomas Jaki
Computational Statistics & Data Analysis|June 4, 2021
Response adaptive designs for Phase II trials with binary endpoint based on context-dependent information measuresKsenia Kasianova, Mark Kelbert, Pavel Mozgunov
Biostatistics (Oxford, England)|August 31, 2018
A benchmark for dose finding studies with continuous outcomesPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Statistics in Medicine|May 9, 2023
A Bayesian multi-arm multi-stage clinical trial design incorporating information about treatment orderingAlessandra Serra, Pavel Mozgunov, Thomas Jaki
Biometrical Journal. Biometrische Zeitschrift|June 13, 2020
Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studiesPavel Mozgunov, Thomas Jaki, Xavier Paoletti
Pageof 6